|
SSRI's
|
Swartz et al 1997: 11 patients; open-label (sertraline, paroxetine, fluoxetine)
|
9/11 had behavioral improvement
|
Diarrhea (1/11) Increased anxiety (1/11)
|
| |
Moretti et al 2003: 8 patients; open-label (paroxetine)
|
Behavioral improvement Reduced caregiver burden
|
Transient nausea (37.5%)
|
| |
Deakin et al 2004: 10 patients; RCTa (paroxetine)
|
No improvement in NPIb or CBIc scores Impairment seen on learning tasks/recognition tasks
|
None reported
|
| |
Ikeda et al 2004: 16 patients; open-label (fluvoxamine)
|
Behavioral improvement Decreased stereotypes
|
None reported
|
|
Trazodone
|
Lebert et al 1999: 14 patients; open-label
|
Improvement in delusions, irritability, aggression, disinhibition (dose-dependent)
|
None reported
|
| |
Lebert et al 2004: 26 patients; randomized controlled trial
|
Improvement in irritability, agitation, depression, eating disorders
|
None reported
|
| |
Lebert et al 2006: 26 patients; open-label extension of 2004 RCT
|
Improved behavioral symptoms; improved NPI score
|
Hypotension (15%)
|
|
Antipsychotics
|
Curtis et al 2000: 1 patient; case report (risperidone)
|
Improved psychosis and social interactions
|
Akathisia Mild parkinsonism
|
| |
Pijnenburg et al 2003: 24 patients; retrospective chart review (majority of patients given typical antipsychotics)
|
Not reported
|
Extrapyramidal symptoms (33%) Sedation (12.5%)
|
|
Others
|
Moretti et al 2004: 20 patients; open-label (rivastigmine)
|
Improved behavioral symptoms Reduced caregiver burden No change in MMSEd score
|
Nausea (25%) Muscle cramps (20%) Blood pressure changes (15%)
|
| |
Goforth et al 2004: 1 patient; case report (methylphenidate)
|
Improved behavioral symptoms
|
None reported
|
